Lilly psoriasis drug impresses; battle nears with Amgen, Novartis

[riky]

Lilly psoriasis drug impresses; battle nears with Amgen, Novartis

An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG. Based on favorable results from Phase III trials, Lilly said Thursday it would seek marketing approval in the first half of 2015 for its drug ixekizumab for patients with moderate-to-severe plaque psoriasis. Cowen and Company analysts have forecast that ixekizumab, if approved, could generate annual sales for Lilly of $600 million by 2020. Like rival injectable drugs being tested by Amgen and Novartis, Lilly's treatment works by blocking an inflammation-causing protein called IL-17, deemed to be a major culprit in the skin disease.

Source: You are not allowed to view links. Register or Login